

UK: Three reasons to be cheerful

The UK's vaccination programme has exceeded all expectations so far, and it's not inconceivable that all adults will have been offered a first dose by the end of the second quarter. The lockdowns also appear to be working, and a spring recovery now looks likely. The major risk now is that a new, vaccine-resistant strain requires a return to lockdown



Britain, Brexit and better times?

ING's James Smith on why we're looking for 5% growth in the UK this year but Brexit continues to bring significant disruption

[Watch video](#)


Despite grim virus news, there are some reasons to be positive

There's not been a great deal to celebrate in the UK over the past few months. Rapidly-changing restrictions and the emergence of a new, 30% more-transmissible strain, have culminated in hospital admissions peaking above the level seen in the spring. But almost one month into the latest national lockdown, there is hope that things are now starting to improve - and there are three positive developments since our last monthly update that are worth flagging.

Firstly, and most importantly, the vaccine rollout has so far exceeded all expectations. The UK is currently averaging around 2.5-3 million doses per week, equivalent to 4% of the population. The majority of over 80s have now received their first dose, and it now looks likely that over 70s will have been offered the jab by mid-February, and over 50s by late-March. It is also not inconceivable

that all adults receive at least one dose by the end of the second quarter, particularly if the single-dose Johnson & Johnson vaccine comes on stream as hoped.

All over 50s could receive the vaccine by the end of this quarter



Source: UK Government, ING projections, Intensive Care National Audit and Research Centre (ICNARC)

Projections assume a smooth increase from the current pace to the new pace by the end of February, which is then constant thereafter

The second piece of good news is that, despite the concerns about the transmissibility of the new UK variant, lockdown has succeeded in bringing down case numbers - and in fact quite rapidly. School closures and a greater emphasis on working from home appears to have helped, while surveys show compliance with the new rules is high.

Finally, the latest GDP data shows that the damage from the lockdowns in November was much milder than first anticipated. The economy shrank by 'only' 2.6%, with most sectors coming away relatively unscathed. While the damage will be greater now than it was then - partly because schools are closed this time - it's clear that the economic impact is quite a bit smaller than last spring.

Piecing all of that together, the outlook beyond the first quarter looks relatively good. The key government priority is to reduce pressure on the health system, and the combination of lockdown and the inoculation of 50-70 year olds (who make up the bulk of ICU admissions), means that significant progress should have been made by Easter. We could see some mild reopening in March (shops?) followed by a gradual reopening through the second quarter. We're currently penciling in a 5% bounce in 2Q GDP, after a 3% fall in the first.

To us, that makes it seem increasingly unlikely that the Bank of England will introduce negative interest rates. There was already limited enthusiasm for the policy on the committee, and that has likely diminished further given the brighter outlook.

New variants pose biggest risk to the recovery

Of course, there's plenty that could yet go wrong. One possibility is that the UK's decision to focus on first doses reduces the effectiveness of the programme, though the tentative evidence so far is that it won't. Data from Israel indicates the Pfizer vaccine is highly effective after the first dose, while AstraZeneca has suggested the efficacy of the second dose is actually stronger with a longer interval of two to three months.

Instead, the biggest threat comes from the new strains. A new, vaccine-resistant version of Covid-19 would cast serious doubt on the recovery later this year - particularly given that it could be several months for new versions of the vaccines to reach people's arms. Mitigating the risk will require strong global progress on vaccinations - something that is likely to take much of this year and beyond.

With the UK likely to be one of the first to inoculate all adults, the government is clearly worried that a spring reopening could be curtailed later in 2021. The fact that the UK is preparing to introduce strict, hotel quarantine for international arrivals indicates how worried ministers are about this.

There are plenty of other reasons for caution too. Higher unemployment is likely to partially offset the boost from pent-up consumer demand, while Brexit disruption will also slow down the recovery (we write about this separately in this monthly update).

We don't expect the UK economy to return to its pre-virus levels until late 2022 or beyond.

Author

James Smith

Developed Markets Economist, UK

james.smith@ing.com

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies).* The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.